Oxokal Sil tablets contain:
-Acido OrtoSilicico stabilized with choline (in order to increase its bioavailability), is a silicon source readily available to humans; silicon is present in the mitochondria of osteoblasts, which are the cells responsible for the formation of bone tissue. During the process of bone calcification, silicon is indispensable and is even greater as an amount compared to the most famous calcium, phosphorus and magnesium. In case of silicon deficiency we could undergo demineralization, osteoporosis, fractures or bruises, difficulties in the post-operative consolidation as well as possible problems of arthritis, arthritis, rheumatism and other diseases of the bones and joints. As we age, body tissues absorb and metabolize lower levels of silicon until they reach an adult consumption of 80% higher than when they are young. Some animal studies indicate that silicon supplementation reduces the number of osteoclasts, the cells responsible for bone resorption, and seems to increase that of osteoblasts responsible for bone formation. Some clinical studies show that a supplement with silicon in women suffering from osteoporosis is associated with a significant increase in bone mineral density. High silicon concentrations are observed near some points where an intensive calcification process occurs, such as in case of fracture. Several studies carried out following fractures related to traumatic shocks or in the case of surgical interventions indicate faster healing and better reinforcement with silicon supplementation.
-Menachinone MK7, essential and biologically active component of Vitamin K2 which intervenes in the formation of bone tissue, favoring proper mineralization;
-Vitamin D3, essential for bone health and functional to fixation of calcium and phosphorus;
-Calcio, the fundamental component for the correct formation and growth of the bones and for the maintenance of normal bone tropism;
-Vitamin K2, essential vitamin for bone well-being, as it promotes osteoblast differentiation and reduces osteoclast differentiation. Furthermore, this vitamin determines the activation of osteocalcin, the main protein of the bone matrix, produced by osteoblasts, characterized by the presence of gamma-carboxyglutamic acid residues; the latter are able to sequestrate calcium ions from the circulation and to bind them to the bone matrix making the skeleton stronger and less susceptible to fractures. In particular, vitamin K2 acts by promoting the gamma-carboxylation of the glutamate residues of the osteocalcin, making it active. In addition, an adequate intake of this vitamin reduces the risk of vascular damage because, by activating a specific protein (MGP), it inhibits calcium deposition in the vessel wall.
* Note Values calculated on a single administration
Several studies have been conducted to investigate the role of vitamin K2 in maintaining good bone function in adults. From these it emerged that the plasma levels of non carboxylated osteocalcin (and therefore not active), increase significantly with increasing age. This increase is associated with reduced bone density, increased bone fragility and a greater risk of fracture. Supplementation for 48 weeks with vitamin K2 has been shown to be effective in reducing blood levels of non-active osteocalcin and raising those of active osteocalcin, suggesting a relationship between vitamin K2 intake and a positive effect on bone metabolism.
This effect has been confirmed later in various studies that have shown that the administration of vitamin K2 helps to preserve the health and strength of the bone tissue. in particular, a clinical study conducted on a group of menopausal women reported how vitamin K2 supplementation reduces osteopenia, increases bone density and keeps bone tissue healthier and more robust than a control group that was administered only placebo; this effect was even more pronounced when vitamin K2 was associated with vitamin D3.